Company news

Kura Oncology, Inc. news in 2025

Kura Oncology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

December 7, 2025

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

December 2, 2025

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

December 1, 2025

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

November 24, 2025

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

November 12, 2025

Kura Oncology to Participate in Upcoming Investor Conference

November 11, 2025

Kura Oncology Reports Third Quarter 2025 Financial Results

November 3, 2025

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

November 2, 2025

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

November 2, 2025

Kura Oncology to Report Third Quarter 2025 Financial Results

October 27, 2025

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

October 23, 2025

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

October 17, 2025

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

September 30, 2025

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

September 28, 2025

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

September 24, 2025

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

September 15, 2025

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

September 2, 2025

Kura Oncology to Participate in Three Upcoming Investor Conferences

August 27, 2025

Kura Oncology Reports Second Quarter 2025 Financial Results

August 6, 2025

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

August 6, 2025

Kura Oncology to Report Second Quarter 2025 Financial Results

July 30, 2025

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

June 11, 2025

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

June 1, 2025

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 31, 2025

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 21, 2025

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 13, 2025

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 5, 2025

Kura Oncology Reports First Quarter 2025 Financial Results

April 30, 2025

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

April 27, 2025

Kura Oncology to Report First Quarter 2025 Financial Results

April 23, 2025

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

April 7, 2025

Kura Oncology to Participate in Stifel Targeted Oncology Forum

March 31, 2025

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

March 25, 2025

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

February 18, 2025

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

February 4, 2025

Kura Oncology Announces Senior Executive Promotions

January 5, 2025

Calls in 2025

Decks in 2025